Abstract
Background. Polyendocrine metabolic ovarian syndrome (PMOS) (polycystic ovary syndrome (PCOS)) remains the
most prevalent endocrinopathy among women of reproductive age (8–13%), characterized by a complex interplay of reproductive,
metabolic, and psychological disturbances. Hyperandrogenism and insulin resistance are the pivotal pathophysiological links,
necessitating the search for effective metabolic correctors.
Objective. To evaluate the therapeutic potential of levocarnitine (the drug Licartin) in correcting hormonal and metabolic
disorders in patients with PCOS based on an analysis of global data and original clinical observations.
Methods. A systematic analysis of current literature and meta-analysis results was performed. Furthermore, three clinical
cases were described involving the administration of levocarnitine at a dosage of 2000 mg (intravenous and oral) in PCOS patients
of various age groups with comorbid conditions (Type 2 Diabetes Mellitus, adenomyosis, and pubertal hyperandrogenism).
Results. It was established that levocarnitine acts as a critical modulator of fatty acid beta-oxidation, contributing to a reduction
in the HOMA-IR index and fasting insulin levels. According to meta-analysis data, adjuvant therapy with levocarnitine increases
the spontaneous ovulation rate by 3.4 times and improves endometrial thickness. Original clinical experience confirmed that the
administration of Licartin (2000 mg) for 20-30 days ensures a 12-15% reduction in free testosterone levels, a reduction in body
weight (primarily visceral fat), and the restoration of menstrual cycle regularity. Additionally, improvements in dermatological
status and cognitive functions were noted.
Conclusions. The integration of levocarnitine (Licartin, 2000 mg) into PCOS treatment protocols achieves a synergistic effect
in normalizing the hormonal background and metabolic profile. The use of both intravenous and oral forms provides a rapid
clinical response, making it an effective tool for intensive initial therapy and preconception care.
References
Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine. 2010;8:41.
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nature Reviews Disease Primers. 2016;2:16057.
Teede HJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
Published in final edited form as: Fertil Steril. 2018 Jul 19;110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004
Shukla A. Polycystic Ovarian Syndrome. Last Update. July 7, 2025.
Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018 Sep;97(39):e12608.
Zhang C, Ma J, Wang W, Sun Y, Sun K. Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Hum Reprod. 2018 Nov 01;33(11):2096-2106
Norman RJ, Teede HJ. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018 Sep 01;209(7):299-300.
Adam LN, Adam LN. Comprehensive overview of polycystic ovary syndrome: Pathophysiology, clinical features, and emerging therapeutic approaches. https://www.sciencedirect.com/science/article/abs/pii/S2451847625000260
Dong J. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. 12 October 2023. https://bmjmedicine.bmj.com/content/2/1/e000548